Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nuveen California Select Tax-Free Income Portfolio is a closed-ended fixed income mutual fund launched by Nuveen Investments Inc. The fund is co-managed by Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC. It invests in the fixed income markets of California. The fund invests in the securities of companies that operate across diversified sectors. It primarily invests in municipal bonds. The fund employs fundamental analysis to create its portfolio. It benchmarks the performance of its portfolio against Barclays Capital California Municipal Bond Index and S&P California Municipal Bond Index. Nuveen California Select Tax-Free Income Portfolio was formed on June 19, 1992 and is domiciled in the United States.

Nuveen California Select Tax-Free Income Portfolio

IMMIX BIOPHARMA TODAY PRESENTED RESULTS AT ASCO FROM ITS U.S. MULTI-CENTER NEXICART-2 PHASE 1/2 CLINICAL TRIAL OF NXC-201, MEETING ITS PRIMARY ENDPOINT.

IMMIX BIOPHARMA ANNOUNCES PRIMARY ENDPOINT MET IN POSITIVE NXC-201 INTERIM RESULTS PRESENTED AT ASCO, ENABLING PATH TO BEST-IN-CLASS THERAPY FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS

IMMIX BIOPHARMA TODAY REPORTED ASCO ABSTRACT RESULTS FROM ITS U.S. MULTI-CENTER NEXICART-2 PHASE 1/2 CLINICAL TRIAL OF NXC-201 DEMONSTRATING STRONG EFFICACY AND FAVORABLE SAFETY.

IMMIX BIOPHARMA ANNOUNCES POSITIVE RESULTS FOR NXC-201 AT ASCO ORAL PRESENTATION, ENABLING PATHWAY TO BEST-IN-CLASS THERAPY FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS

 ORAL PRESENTATION TUESDAY, JUNE 3, 2025 IN CHICAGO  LOS ANGELES, APRIL 23, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND OTHER SERIOUS DISEASES, TODAY ANNOUNCED THAT PHASE 1/2 INTERIM READOUT DATA FROM ITS U.S. NXC-201 NEXICART-2 TRIAL IN RELAPSED/REFRACTORY AL AMYLOIDOSIS HAS BEEN SELECTED FOR ORAL PRESENTATION AT THE UPCOMING 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING (ASCO 2025) BEING HELD IN CHICAGO, ILLINOIS, MAY 30  JUNE 3, 2025, PRESENTED BY LEAD INVESTIGATOR HEATHER LANDAU, M.D., DIRECTOR OF AMYLOIDOSIS PROGRAM AND A BONE MARROW TRANSPLANT SPECIALIST & CELLULAR THERAPIST AT MEMORIAL SLOAN-KETTERING CANCER CENTER IN NEW YORK.

IMMIX BIOPHARMA'S NXC-201 NEXICART-2 CLINICAL TRIAL DATA SELECTED FOR ORAL PRESENTATION AT ASCO 2025

FDA RMAT DESIGNATION FOLLOWS POSITIVE PROOF-OF-CONCEPT U.S. CLINICAL DATA FROM THE NXC-201 NEXICART-2 CLINICAL TRIAL IN RELAPSED/REFRACTORY AL AMYLOIDOSIS RMAT DESIGNATION POTENTIALLY STREAMLINES THE PATH TO MARKET APPROVAL BY ALLOWING FREQUENT INTERACTIONS WITH FDA AND ROUTES TO FDA ACCELERATED APPROVAL AND PRIORITY REVIEW ENROLLMENT IN NEXICART-2 STUDY ACCELERATING; NEXT UPDATE PLANNED FOR H1 2025 LOS ANGELES,CA, FEB. 10, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (NASDAQ: IMMX) (IMMIXBIO, COMPANY, WE OR US, IMMX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND SELECT IMMUNE-MEDIATED DISEASES, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED RMAT DESIGNATION TO STERICALLY-OPTIMIZED CAR-T NXC-201 FOR THE TREATMENT OF RELAPSED/REFRACTORY AL AMYLOIDOSIS. AS OF JUNE 2024 PUBLIC INFORMATION, FDA APPROVED LESS THAN HALF OF RMAT APPLICATIONS SUBMITTED TO THE AGENCY DURING THE LAST EIGHT YEARS.

IMMIX BIOPHARMA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR NXC-201, STERICALLY-OPTIMIZED CAR-T FOR RELAPSED/REFRACTORY AL AMYLOIDOSIS

LOS ANGELES, JAN. 07, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (NASDAQ: IMMX) (IMMIXBIO, COMPANY, WE OR US, IMMX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND SELECT IMMUNE-MEDIATED DISEASES, TODAY ANNOUNCED SUCCESSFUL COMPLETION OF THE SIX-PATIENT PHASE 1B SAFETY RUN-IN SEGMENT IN THE U.S. NEXICART-2 STUDY OF NXC-201, AN INVESTIGATIONAL CAR-T THERAPY, IN PATIENTS RELAPSED/REFRACTORY (R/R) AL AMYLOIDOSIS. ACHIEVEMENT OF THIS MILESTONE IS EXPECTED TO ACCELERATE ENROLLMENT ACROSS U.S. STUDY SITES BEGINNING IN JANUARY 2025.

IMMIX BIOPHARMA ACCELERATES ENROLLMENT IN U.S. AL AMYLOIDOSIS TRIAL OF NXC-201 CAR-T

CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) CELL THERAPY NXC-201 IS A NOVEL APPROACH TO TREAT RELAPSED/REFRACTORY AL AMYLOIDOSIS NXC-201 DEMONSTRATED COMPELLING CLINICAL ACTIVITY, RAPID AND DEEP COMPLETE RESPONSES IN FRAIL AND RESISTANT RELAPSED/REFRACTORY AL AMYLOIDOSIS PATIENTS LOS ANGELES, DEC. 16, 2024 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING CELL THERAPIES FOR AL AMYLOIDOSIS AND SELECT IMMUNE-MEDIATED DISEASES, ANNOUNCED TODAY THE JOURNAL OF CLINICAL ONCOLOGY (JCO) PUBLISHED NXC-201 CLINICAL RESULTS IN RELAPSED/REFRACTORY AL AMYLOIDOSIS. THE DATA REPORTED ON 16 ENROLLED PATIENTS IN NEXICART-1 WHO HAD RECEIVED A MEDIAN 4 PRIOR LINES OF THERAPY PRIOR TO TREATMENT WITH NXC-201.

JOURNAL OF CLINICAL ONCOLOGY PUBLISHES NXC-201 POSITIVE CLINICAL RESULTS IN RELAPSED/REFRACTORY AL AMYLOIDOSIS

NEW YORK--(BUSINESS WIRE)--NUVEEN CLOSED-END FUNDS TODAY ANNOUNCED THAT THE BOARD OF TRUSTEES OF THE FUNDS HAS APPROVED THE REGULAR MONTHLY AND QUARTERLY DISTRIBUTIONS. IN ADDITION, THE BOARD OF TRUSTEES HAS APPROVED UPDATED DISTRIBUTION POLICES DESCRIBED BELOW UNDER MONTHLY & QUARTERLY DISTRIBUTIONS FOR THE NUVEEN PREFERRED & INCOME OPPORTUNITIES FUND (NYSE: JPC), NUVEEN PREFERRED AND INCOME TERM FUND (NYSE: JPI), NUVEEN VARIABLE RATE PREFERRED & INCOME FUND (NYSE: NPFD), NUVEEN.

Nuveen California Select Tax-Free Income Portfolio

NXC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Nuveen California Select Tax-Free Income Portfolio

NXC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NXC